Certain Balance Sheet Components (Tables)

9 Months Ended

Dec. 31, 2021

Other Liabilities Disclosure [Abstract]

Schedule of Cash and Cash Equivalents

The following represents a reconciliation of cash and cash equivalents in the unaudited condensed consolidated balance sheets to total cash, cash equivalents and restricted cash in the unaudited condensed consolidated statements of cash flows (in thousands):

	December 31,
	2021		2020
Cash and cash equivalents	$	457,742	$	713,523
Restricted cash	10,100		2,987
Total cash, cash equivalents and restricted cash	$	467,842	$	716,510

Schedule of Inventory

As of December 31, 2021 and March 31, 2021, inventories consisted of the following (in thousands):

	December 31, 2021		March 31, 2021
Raw materials	$	823	$	1,390
Work in process	1,405		773
Finished goods	4,509		448
Total inventories	$	6,737	$	2,611

Schedule of Accrued Liabilities

As of December 31, 2021 and March 31, 2021, accrued expenses and other current liabilities consisted of the following (in thousands):

	December 31, 2021		March 31, 2021
Accrued compensation-related expenses	$	22,201	$	20,571
Accrued sales discounts, rebates, and allowances	15,549		1,315
Accrued R&D expenses	6,463		8,544
Accrued commercial expenses	8,309		7,770
Accrued other expenses	5,259		5,315
Accrued professional fees	642		935
Deferred product revenue	—		162
Total accrued expenses and other current liabilities	$	58,423	$	44,612